Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Q3 FY2018 Earnings Presentation
9 slides from Sonoma Pharmaceuticals's earnings presentation, Feb 7, 2018
Slide 1: Sonoma Pharmaceuticals Third Quarter FY2018 Results
NASDAQ: SNOA SONOMA PHARMACEUTICALS THIRD QUARTER FY2018 RESULTS February 7, 2018
Slide 2: Agenda
NASDAQ: SNOA Page Agenda 2 Welcome / Introduction December 31, 2017 Highlights Financial Review Q+A Jim Schutz Jim Schutz Bob Miller
Slide 3: Forward-Looking Statement
NASDAQ: SNOA Page Forward - Looking Statement Except for historical information herein, matters set forth in this presentation are forward - looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial a
Slide 4: Results from the Quarter Ended December 2017
NASDAQ: SNOA Page Results from the Quarter Ended December 2017 Total Net Revenues = $4,834,000 * • Product revenue up 46% versus same period last year • US Product revenue up 27% versus quarter ended 30 Sep 2017 4 US Dermatology Revenue = $2,207,000 * • Up 78% versus same period last year • Up 36% v
Slide 5: Fiscal YTD Milestones
NASDAQ: SNOA Page Fiscal YTD Milestones Jan - Three UAE approvals for blepharitis , chronic rhinosinusitis and oral care Nov + Dec - Three FDA approvals to expand indications to add antimicrobial language Oct - Seven Brazilian dermatology approvals Sep - Launched Loyon, indicated for scaling and ery
Slide 6: Differentiated, Effective Solutions for atopic dermatitis and eczema
NASDAQ: SNOA Page 6 Differentiated, Effective Solutions … for atopic dermatitis and eczema Ceramax ™ with Lipogrid ® Technology has been designed to control release and penetrate deep. Fluorescent microscopy shows the lipids in Lipogrid® Technology penetrate beyond the stratum corneum (SC) into the
Slide 7: Dec 2017 QTR vs Dec 2016 QTR & Sept 2017 QTR
Dec 2017 QTR vs Dec 2016 QTR & Sept 2017 QTR 7 Quarter Ended Quarter Ended Dec 31 , 2016 Quarter Ended Sept 30, 2017 Dec 31, 2017 œ Amount Variance ¸ Amount Variance ¸ Total net revenues $4,843 $3,361 $1,482 44 ¸ $4,325 $518 12 ¸ Product revenues $4,647 $3,174 $1,473 46 ¸ $4,144 $503 12 ¸ U.S. reven
Slide 8: Prescription Units Shipped for Dermatology Product Lines
NASDAQ: SNOA Page 8 Prescription Units Shipped for Dermatology Product Lines 0 1,106 2,724 3,361 4,059 3,769 4,190 6,201 6,827 7,175 5,712 6,757 7,327 7,863 0 39 1,043 2,305 3,103 2,833 3,382 4,298 4,405 4,204 3,488 4,914 4,938 4,930 0 134 582 222 318 414 921 1,217 1,733 1,699 0 689 1,410 1,908 1,44
Slide 9: Quarterly revenue by dermatology product line
NASDAQ: SNOA Total Q4 $2,552,720 + 7% Total Q3 $2,393,001 + 15% Total Q4 $2,791,258 + 17% Total Q2 $2,088,619 + 26% Total Q4 $2,791,258 + 17% 9 Average Quarter over Quarter Growth for Last 4/ 6 Quarters: • Total Prescription Units Sold Quarterly Growth of 19%/ 24% • Ceramax (skin repair) Quarterly G
Sonoma Pharmaceuticals — Q3 FY2018 Earnings Presentation on 6ix